Steppogenin

Steppogenin

SCHEMBL677660

O=C1CC(c2ccc(O)cc2O)Oc2cc(O)cc(O)c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 6/20 1.00
PTGS1 P23219 1/20 1.00
PTGS2 P35354 1/20 1.00
TYR P14679 1/20 1.00
CYP3A4 P08684 5/20 0.72
CYP1A1 P04798 4/20 0.72
CYP1A2 P05177 4/20 0.72
CYP1B1 Q16678 4/20 0.72
TTR P02766 4/20 0.72
CYP2C19 P33261 3/20 0.72
HSD17B10 Q99714 3/20 0.72
MEN1 O00255 2/20 0.72
KMT2A Q03164 2/20 0.72
CYP2C9 P11712 2/20 0.72
CA12 O43570 2/20 0.72
SLCO2B1 O94956 2/20 0.72
CA4 P22748 2/20 0.72
PSMB5 P28074 2/20 0.72
CA7 P43166 2/20 0.72
ALOX12 P18054 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Steppogenin SCHEMBL29649083 1.00 CYP19A1 (1.00) CYP19A1PTGS1PTGS2TYRCYP3A4
Steppogenin SCHEMBL6822729 1.00 CYP19A1 (1.00) CYP19A1PTGS1PTGS2TYRCYP3A4
SCHEMBL26406007 0.89 CYP19A1 (0.81) CYP19A1PTGS1PTGS2TYRCYP3A4
SCHEMBL26406011 0.89 CYP19A1 (0.81) CYP19A1PTGS1PTGS2TYRCYP3A4
SCHEMBL26125489 0.89 CYP19A1 (0.81) CYP19A1PTGS1PTGS2TYRCYP3A4
SCHEMBL28035035 0.87 CYP19A1 (0.78) CYP19A1PTGS1PTGS2TYRCYP3A4
SCHEMBL29650043 0.87 CYP19A1 (0.78) CYP19A1PTGS1PTGS2TYRCYP3A4
SCHEMBL27920300 0.87 CYP19A1 (0.77) CYP19A1PTGS1PTGS2TYRCYP3A4
Artocarpanone SCHEMBL29649131 0.87 CYP19A1 (0.77) CYP19A1PTGS1PTGS2TYRCYP3A4
Artocarpanone SCHEMBL17656773 0.87 CYP19A1 (0.77) CYP19A1PTGS1PTGS2TYRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105001068-A One-step green synthesis method for hydroxychalcone and flavanone UNIV JIANGNAN 2015-10-28 CN claimed
US-20140018552-A1 USE OF COMPOUNDS ISOLATED FROM MORUS BARK DONG WHA PHARM. CO., LTD. (KR) 2014-01-16 US claimed
CN-121015674-A Use of NOTCH1 inhibitors or compounds in the treatment of diabetic nephropathy 重庆第二师范学院 2025-11-28 CN disclosed
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2024-01-18 US disclosed
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2024-01-18 US disclosed
US-10435673-B2 Method for the biotechnological production of flavonoids SYMRISE AG (DE) 2019-10-08 US disclosed
US-20190142940-A1 Method and system for effecting changes in pigmented tissue MOAZED KAMBIZ THOMAS (US) 2019-05-16 US disclosed
US-20180135029-A1 METHOD FOR THE BIOTECHNOLOGICAL PRODUCTION OF FLAVONOIDS SYMRISE AG (DE) 2018-05-17 US disclosed
US-20180135029-A1 METHOD FOR THE BIOTECHNOLOGICAL PRODUCTION OF FLAVONOIDS SYMRISE AG (DE) 2018-05-17 US disclosed
US-9744237-B2 Method and system for effecting changes in pigmented tissue MOAZED KAMBIZ THOMAS (US) 2017-08-29 US disclosed
EP-3002335-A1 Process for the biotechnological production of flavonoids Symrise AG (DE) 2016-04-06 EP disclosed
CN-103476408-A Application of compound separated from cortex mori DONG WHA PHARM CO LTD 2013-12-25 CN disclosed
WO-2012134126-A3 USE OF COMPOUNDS ISOLATED FROM MORUS BARK DONG WHA PHARM. CO., LTD. (KR) 2013-01-03 WO disclosed
WO-2012134126-A2 USE OF COMPOUNDS ISOLATED FROM MORUS BARK DONG WHA PHARM. CO., LTD. (KR) 2012-10-04 WO disclosed
WO-2012134126-A2 USE OF COMPOUNDS ISOLATED FROM MORUS BARK DONG WHA PHARM. CO., LTD. (KR) 2012-10-04 WO disclosed
US-20120207809-A1 Method and system for effecting changes in pigmented tissue MOAZED KAMBIZ THOMAS (US) 2012-08-16 US disclosed
US-20120076848-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2012-03-29 US disclosed
US-20110280909-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2011-11-17 US disclosed
WO-2011011065-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2011-01-27 WO disclosed
WO-2010087983-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018552-A1 USE OF COMPOUNDS ISOLATED FROM MORUS BARK AGER, MORF4L1, HNRNPF CYP19A1 4159/4885PTGS1 267/4885PTGS2 507/4885
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS THPO, SERPINB1, SERPINC1 CYP19A1 1668/4885PTGS1 225/4885PTGS2 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.